Across TCGA pan-cancer cohorts, KXD1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KXD1 data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher KXD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KXD1 expression acts as an unfavorable survival marker.
SKCM and LUAD are the cancer types where KXD1 Mutation most reproducibly stratifies survival.